U.S. pharma large copyright scrapped two experimental weight loss products last yr—a once-each day tablet, lotiglipron, resulting from elevated liver enzymes along with a twice-day-to-day tablet, danuglipron, on account of potent Uncomfortable side effects—but CEO Albert Bourla has stated the company is determined to “Enjoy and gain” inside